A B S T R A C T

Background
In acute asthma inhaled β2-agonists are often administered to relieve bronchospasm by wet nebulisation, but some have argued that metered-dose inhalers with a holding chamber (spacer) can be equally effective. Nebulisers require a power source and need regular maintenance, and are more expensive in the community setting.
Objectives
To assess the effects of holding chambers (spacers) compared to nebulisers for the delivery of ß2-agonists for acute asthma.
Search strategy
We searched the Cochrane Airways Group Trial Register and reference lists of articles. We contacted the authors of studies to identify additional trials. Date of last search: January 2008.
Selection criteria
Randomised trials in adults and children (from two years of age) with asthma, where spacer ß2-agonist delivery was compared with wet nebulisation.
Data collection and analysis
Two reviewers independently applied study inclusion criteria (one reviewer for the first version of the review), extracted the data and assessed trial quality. Missing data were obtained from the authors or estimated. Results are reported with 95% confidence intervals (CI).
Main results
This review has been updated in January 2008 and two new trials have been added. 2295 children and 614 adults are now included in 27 trials from emergency room and community settings. In addition, six trials on in-patients with acute asthma (213 children and 28 adults) have been reviewed. Method of delivery of ß2-agonist did not appear to affect hospital admission rates. In adults, the relative risk of admission for spacer versus nebuliser was 0.97 (95% CI 0.63 to 1.49). The relative risk for children was 0.72 (95% CI: 0.47 to 1.09). In children, length of stay in the emergency department was significantly shorter when the spacer was used, with a mean
